

In-Hospital Switching Between Clopidogrel and Prasugrel in Patients With Myocardial Infarction Treated With Percutaneous Coronary Intervention

Circulation: Cardiovascular Interventions

7, 585-593

DOI: [10.1161/circinterventions.114.001555](https://doi.org/10.1161/circinterventions.114.001555)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pharmacodynamic and Clinical Implications of Switching Between P2Y12 Receptor Antagonists. <i>Critical Pathways in Cardiology</i> , 2014, 13, 156-158.	0.2	9
2	The Association of Previous Revascularization With In-Hospital Outcomes in Acute Myocardial Infarction Patients. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1954-1962.	1.1	14
3	Prasugrel in Clopidogrel Nonresponders. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1571-1573.	1.1	1
4	Dual antiplatelet therapy: optimal timing, management, and duration. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 198-204.	1.4	32
5	Controversies in Cardiology. , 2015, , .		0
6	Switching between thienopyridines in patients with acute myocardial infarction and quality of care. <i>Open Heart</i> , 2016, 3, e000384.	0.9	9
7	Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. <i>Heart</i> , 2016, 102, 1221-1229.	1.2	3
8	Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization. <i>International Journal of Cardiology</i> , 2016, 223, 854-859.	0.8	10
10	Transition between ticagrelor and two different doses of clopidogrel at hospital discharge in patients with acute coronary syndrome submitted to percutaneous coronary intervention. <i>Revista Brasileira De Cardiologia Invasiva (English Edition)</i> , 2016, 24, 30-34.	0.1	0
11	Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients. <i>European Heart Journal Supplements</i> , 2016, 18, F19-F26.	0.0	15
12	Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations. <i>American Heart Journal</i> , 2016, 176, 44-52.	1.2	23
13	In-hospital switching from clopidogrel to prasugrel following thrombolysis for ST-elevation myocardial infarction: a 3-year single center experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016, 5, 271-276.	0.4	1
14	The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 83-91.	0.8	6
15	Switching P2Y12-receptor inhibitors in patients with coronary artery disease. <i>Nature Reviews Cardiology</i> , 2016, 13, 11-27.	6.1	154
16	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017, 188, 73-81.	1.2	25
17	Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of Tj ETQq1 1 0.784314 rgBT /Overl... 38, 3070-3078.	1.0	316
18	Switching P2Y12 Receptor Inhibiting Therapies. <i>Interventional Cardiology Clinics</i> , 2017, 6, 67-89.	0.2	10
19	Association of measured platelet reactivity with changes in P2Y 12 receptor inhibitor therapy and outcomes after myocardial infarction: Insights into routine clinical practice from the Treatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) study. <i>American Heart Journal</i> . 2017. 187. 19-28.	1.2	14

#	ARTICLE	IF	CITATIONS
20	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
21	In-stent thrombosis when switching ticagrelor to clopidogrel after percutaneous coronary intervention. <i>Platelets</i> , 2017, 28, 305-309.	1.1	1
22	Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. <i>American Heart Journal</i> , 2017, 183, 62-68.	1.2	60
23	Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. <i>Lancet</i> , 2017, 390, 1747-1757.	6.3	443
24	Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE-ACS (Treatment With ADP Receptor) Tj ETQq0,0,0 rgBT /QOverlock 1	1.6	2
25	Impact of Chronic Antiplatelet Therapy on Infarct Size and Bleeding in Patients With Acute Myocardial Infarction. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 407-413.	1.0	2
26	Early P2Y ₁₂ Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 852-863.	1.8	0
27	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , 2018, 34, 319-329.	0.8	22
28	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	0.8	181
29	Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y ₁₂ Inhibition by Clopidogrel to the Use of New P2Y ₁₂ Inhibitors. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 674-689.	0.9	3
30	Studies on drug switchability showed heterogeneity in methodological approaches: a scoping review. <i>Journal of Clinical Epidemiology</i> , 2018, 101, 5-16.	2.4	2
31	P2Y ₁₂ inhibitors for the treatment of acute coronary syndrome patients undergoing percutaneous coronary intervention: current understanding and outcomes. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 717-727.	0.6	4
32	Switching between P2Y ₁₂ antagonists â€œ From bench to bedside. <i>Vascular Pharmacology</i> , 2019, 115, 1-12.	1.0	8
33	De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. <i>Chinese Medical Journal</i> , 2019, 132, 197-210.	0.9	11
34	De-Escalation of Treatment With Oral P2Y ₁₂ Receptor Inhibitors: Current Status and Perspectives. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 304-314.	1.0	4
35	Switching of Oral P2Y ₁₂ Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis. <i>Clinical Drug Investigation</i> , 2019, 39, 275-283.	1.1	1
36	De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Platelets</i> , 2020, 31, 15-25.	1.1	13
37	Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting. <i>Genetics in Medicine</i> , 2020, 22, 160-169.	1.1	41

#	ARTICLE	IF	CITATIONS
38	Prospective <i>CYP2C19</i> Genotyping to Guide Antiplatelet Therapy Following Percutaneous Coronary Intervention. <i>Circulation Genomic and Precision Medicine</i> , 2020, 13, e002640.	1.6	39
39	Impact of Implementing <i>CYP2C19</i> Genotype-Guided Antiplatelet Therapy on P2Y12 Inhibitor Selection and Clinical Outcomes in Acute Coronary Syndrome Patients After Percutaneous Coronary Intervention: A Real-World Study in China. <i>Frontiers in Pharmacology</i> , 2020, 11, 582929.	1.6	13
40	Ticagrelor Utilization in Patients With Non-ST Elevation Acute Coronary Syndromes in Romania. <i>American Journal of Therapeutics</i> , 2021, 28, e271-e283.	0.5	0
41	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , 2021, 17, 59-66.	1.4	21
42	Characteristics and clinical outcomes of patients with de-escalation from prasugrel to clopidogrel after acute myocardial infarction - Insights from the prospective Japan Acute Myocardial Infarction Registry (JAMIR) -. <i>Journal of Cardiology</i> , 2021, 78, 99-106.	0.8	3
43	Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. <i>EuroIntervention</i> , 2017, 13, 459-466.	1.4	83
44	DAPT After Stenting in Stable and Acute Coronary Syndromes- Does the Drug Combination Really Matter?. , 2015, , 255-269.		0
45	Antiplatelet Therapy in Acute Coronary Syndrome. <i>Sklifosovsky Journal Emergency Medical Care</i> , 2022, 10, 769-777.	0.3	0
46	Predictors and long-term outcomes of in-hospital switching from clopidogrel to ticagrelor among patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2022, , .	0.7	0
47	Predictors of in-hospital de-escalation of P2Y12 inhibitors to clopidogrel in patients with acute myocardial infarction treated with percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	1
48	Safety and Efficacy of Selective, Clopidogrel-Based Strategies in Acute Coronary Syndrome: A Study-Level Meta-analysis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1732-1743.	1.8	4
49	De-escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: An Updated Meta-analysis and Trial Sequential Analysis of 21 Studies and 38,741 Patients. <i>Journal of Cardiovascular Pharmacology</i> , 2022, 79, 873-886.	0.8	1